[PDF][PDF] Antibody evasion by the P. 1 strain of SARS-CoV-2
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
[HTML][HTML] Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …
began when the first sequence was published, and this forms the basis for …
Cross-reacting antibodies enhance dengue virus infection in humans
W Dejnirattisai, A Jumnainsong, N Onsirisakul, P Fitton… - Science, 2010 - science.org
Dengue virus co-circulates as four serotypes, and sequential infections with more than one
serotype are common. One hypothesis for the increased severity seen in secondary …
serotype are common. One hypothesis for the increased severity seen in secondary …
Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
W Dejnirattisai, P Supasa, W Wongwiwat… - Nature …, 2016 - nature.com
Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease.
The recent explosive outbreak of ZIKV in South America has led to widespread concern, with …
The recent explosive outbreak of ZIKV in South America has led to widespread concern, with …
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
W Dejnirattisai, W Wongwiwat, S Supasa, X Zhang… - Nature …, 2015 - nature.com
Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million
infections occurring annually. To gain insight into dengue immunity, we characterized 145 …
infections occurring annually. To gain insight into dengue immunity, we characterized 145 …
[HTML][HTML] Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum
W Dejnirattisai, RH Shaw, P Supasa, C Liu… - Lancet (London …, 2022 - ncbi.nlm.nih.gov
According to WHO, SARS-CoV-2 is estimated to have caused 265 million infections and
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
[PDF][PDF] The antigenic anatomy of SARS-CoV-2 receptor binding domain
Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
…, G Liu, X Yao, Z Yin, D Dong, W Dejnirattisai… - Nature …, 2020 - nature.com
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
